Form 4: Madrigal General Counsel Boosts Equity Holdings

Madrigal Pharmaceuticals' General Counsel, Shannon T. Kelley, increased her beneficial ownership through RSU and stock option grants, alongside a tax-related share sale.

Summary

• Shannon T. Kelley, General Counsel of Madrigal Pharmaceuticals, Inc. (MDGL), acquired 4,017 shares of common stock through a Restricted Stock Unit (RSU) grant on March 4, 2026.
• These RSUs vest as to 25% of the shares on each of March 4, 2027, March 4, 2028, March 4, 2029, and March 4, 2030, contingent on continued service.
• Kelley also acquired 5,022 stock options on March 4, 2026, with an exercise price of $434.80 per share and an expiration date of March 4, 2036.
• The stock options vest as to 25% on March 4, 2027, and then 6.25% on the last day of each successive three-month period, contingent on continued service.
• On March 6, 2026, 360 shares of common stock were sold at a price of $431.94 per share to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Kelley beneficially owns 12,138 shares of common stock and 5,022 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as moderately positive. The equity grants demonstrate continued commitment to the executive and align her interests with shareholders, which is generally a favorable signal, despite the routine tax-related share sale.

Positives

• The grant of 4,017 Restricted Stock Units and 5,022 stock options aligns the General Counsel's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice to retain and motivate key executives.

Negatives

• A sale of 360 shares occurred to cover tax withholding obligations, which is a routine event and not indicative of a discretionary sale by the insider.

Future Outlook

The future outlook for Shannon T. Kelley's equity holdings is tied to the vesting schedules of the granted Restricted Stock Units and stock options, which extend through March 2030 and March 2036, respectively, contingent on her continued service with Madrigal Pharmaceuticals.

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units and stock options, are a common component of executive compensation packages in the biotechnology and pharmaceutical industries. These grants are designed to align the long-term interests of executives with those of shareholders, encouraging sustained performance and value creation. The tax-related sale is a standard, non-discretionary event associated with RSU vesting.

Stakeholder Impact

• Shareholders: The equity grants align the General Counsel's financial incentives with shareholder value creation, potentially leading to more focused long-term decision-making.
• Employees: The compensation structure for a key executive may serve as a benchmark or motivator for other employees within the company.

Next Steps

• Continued service by Shannon T. Kelley with Madrigal Pharmaceuticals to ensure vesting of RSUs and stock options.
• Periodic vesting of RSUs and stock options on specified dates between March 2027 and March 2030 (for RSUs) and quarterly thereafter (for options).

Key Dates

Recommendation

The filing details routine executive compensation through equity grants and a non-discretionary tax-related share sale. While the grants are a positive signal of executive alignment, this Form 4 alone does not provide sufficient new information to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' stance, acknowledging the ongoing commitment of key management.

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Executive Compensation, Equity Grant